Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
H.P. Acthar Gel
Mallinckrodt unloads its CDMO for $250M as potential liabilities mount
Tuesday, September 10, 2019
Troubled Mallinckrodt is selling sell its CDMO unit for up to $250 million, but that is a drop in the bucket of what it may need going forward.
Mallinckrodt hit with kickback suit same day as settlement
Wednesday, June 5, 2019
Chafing under federal kickback charges tied to its H.P. Acthar Gel, Mallinckrodt appeared to be clear with a settlement in the works. Not so fast.
DOJ joins the fray in Mallinckrodt's Acthar whistleblower suits
Wednesday, May 1, 2019
Bad news for Mallinckrodt: Federal prosecutors will join plaintiffs in whistleblower suits alleging illegal marketing of Questcor's H.P. Acthar Gel.
Mallinckrodt invests $100M in its BioVectra CDMO
Wednesday, March 6, 2019
Mallinckrodt's BioVectra CDMO, which makes the API for its controversial H.P. Acthar Gel, is expanding and getting some Canadian tax dollars to help.
Mallinckrodt hit back at Acthar whistleblower, lawsuit claims
Friday, April 13, 2018
Mallinckrodt is under more scrutiny this week with a whistleblower lawsuit alleging fraud, retaliation and more.
Mallinckrodt foiled Acthar rival to hike prices 85,000%: lawsuit
Tuesday, October 31, 2017
A set of Medicare payers accuse embattled Mallinckrodt of violating antitrust law to stifle competition for its $1 billion-plus Acthar Gel.
JAMA piece resurrects questions over cost of Mallinckrodt's Acthar
Wednesday, September 13, 2017
A new study in JAMA has put the focus back on the price of Mallinckrodt's controversial med, H.P. Acthar gel.
Mallinckrodt med falls into pricing probe
Tuesday, May 30, 2017
The painkiller Ofirmev doubled in price after Mallinckrodt bought it—and it's the latest investigative target of Sen. Claire McCaskill. But this probe isn’t so cut-and-dried.
Short-seller Andrew Left levels new charges at Mallinckrodt
Wednesday, May 18, 2016
Mallinckrodt has faced plenty of criticism about H.P. Acthar Gel, what with pricing controversies, federal probes and basic questions about its efficacy. Now, short-seller Andrew Left has issued a new challenge.